Expansion of these NK cells with interleukin-2 (IL-2) led to a loss of superior activation of KIR2DS2 high NK cells relative to NK cells lacking KIR2DL3/L2/S2 expression but not compared with the ...

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...

Our findings also showed that IFNγ + CD3 + T cells induced by BCG and antigens highly express IL-2, while IL-2 expression unaltered by Mtb pathogen stimulation and diminished in TB patients.

allowing for sustained immune stimulation. In preclinical models, a weekly dosing regimen in mice provided durable immune responses and tumor growth inhibition. These mouse ortholog variants ...

The Malmberg lab focuses on understanding the cellular and molecular mechanisms underlying the formation and diversification of human NK cell repertories. A central aspect of these studies is to ...

(NASDAQ: IBRX), announced today that the first patients have been dosed in an initial trial studying the potential of the company’s CAR-NK cell therapy ... the company’s IL-15 superagonist ...

Immunotherapy innovator ImmunityBio (IBRX) announced that the first patients have been dosed in an initial trial studying the potential of the company’s CAR-NK cell therapy targeting CD-19 in ...

Company’s first clinical trial studying CAR-NK (CD19 t-haNK) cellular therapy in liquid tumors First natural killer cell-based cellular therapy study conducted in the continent ... a phase 1 ...

Nov. 4, 2024 — Stem cells grown in microgravity aboard the International Space Station (ISS) have unique qualities that could one day help accelerate new biotherapies and heal complex disease ...